Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 … Read more
Jiangsu Recbio Technology Co., Ltd. (G93) - Total Assets
Latest total assets as of June 2025: €1.54 Billion EUR
Based on the latest financial reports, Jiangsu Recbio Technology Co., Ltd. (G93) holds total assets worth €1.54 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jiangsu Recbio Technology Co., Ltd. - Total Assets Trend (2021–2024)
This chart illustrates how Jiangsu Recbio Technology Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jiangsu Recbio Technology Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Recbio Technology Co., Ltd.'s total assets of €1.54 Billion consist of 33.8% current assets and 66.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 16.4% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €62.30 Million | 3.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €37.43 Million | 1.9% |
| Goodwill | €9.30 Million | 0.5% |
Asset Composition Trend (2021–2024)
This chart illustrates how Jiangsu Recbio Technology Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Recbio Technology Co., Ltd.'s current assets represent 33.8% of total assets in 2024, a decrease from 67.5% in 2021.
- Cash Position: Cash and equivalents constituted 16.4% of total assets in 2024, down from 61.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 3.2% of total assets.
Jiangsu Recbio Technology Co., Ltd. Competitors by Total Assets
Key competitors of Jiangsu Recbio Technology Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Jiangsu Recbio Technology Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Jiangsu Recbio Technology Co., Ltd. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Jiangsu Recbio Technology Co., Ltd. is currently not profitable relative to its asset base.
Jiangsu Recbio Technology Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.32 | 1.17 | 1.17 |
| Quick Ratio | 0.28 | 0.96 | 0.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-599.79 Million | € 113.72 Million | € 113.72 Million |
Jiangsu Recbio Technology Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Jiangsu Recbio Technology Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -11.3% |
| Total Assets | €1.94 Billion |
| Market Capitalization | $55.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Recbio Technology Co., Ltd.'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jiangsu Recbio Technology Co., Ltd.'s assets decreased by 11.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jiangsu Recbio Technology Co., Ltd. (2021–2024)
The table below shows the annual total assets of Jiangsu Recbio Technology Co., Ltd. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €1.94 Billion | -11.25% |
| 2023-12-31 | €2.19 Billion | -5.34% |
| 2022-12-31 | €2.31 Billion | +20.34% |
| 2021-12-31 | €1.92 Billion | -- |